Boards: Align Technologies, Inc., The Engine, built by MIT; Illumina, Inc., Nevro Corporation.

Susan (Sue) Siegel brings extensive expertise to enterprises, having served as a CEO, venture capitalist, and board director in the life sciences and health-care industries. As a board director, she has served on public and private corporate boards, across big and small companies, and for nonprofit organizations. She is a visionary leader known for identifying and seizing transformative opportunities that help organizations create returns for shareholders, build new markets, and impact lives. Sue is recognized as a builder of ultra-high-performing teams and directs her energies toward unlocking untapped potential in individuals and across teams to drive growth.

For more than 20 years, Sue has served on more than 20 public and private company boards as well as at nonprofit organizations. Her current board portfolio includes Align Technology, Illumina, Nevro Corp., and KFF (formerly the Kaiser Family Foundation). She is chair of the board of The Engine, built by the Massachusetts Institute of Technology (MIT). Sue has served on a range of board committees spanning audit, compensation, nominating and governance, technology, investment, and special; on several of these, she has served as chair. She was named one of the most influential leaders in corporate governance by the National Association of Corporate Directors (NACD) as part of its 2023 NACD Directorship 100^™.

Sue’s public service includes President Obama’s Working Group for starting the Precision Medicine Initiative, which led to the creation of All of US. She also was a founding board member of the National Center for Advancing Translational Science and a selection judge for White House Fellows across administrations. She served on the nonprofit boards of the National Venture Capital Association and Silicon Valley’s Tech Interactive. She currently cochairs Stanford Medicine’s Board of Fellows and is a member of the Innovation Growth Board of Mass General Brigham and its Innovator Development and Growth Division.

During her business career, Sue served chief innovation officer of General Electric (GE), CEO of GE Ventures & Licensing, and CEO of Healthymagination. Prior to that, she was a venture capital general partner at Mohr Davidow Ventures, leading investments in precision health and life sciences. During the early days of the human genome project, Sue led Affymetrix, one of the fastest-growing Silicon Valley–based genomics companies of the time. She drove its growth from a pre-revenue start-up to a multibillion-dollar Nasdaq-listed company that helped shape the emerging genomics industry, including addressing emerging bioethical issues.

Sue is currently on the faculty at MIT’s Sloan School of Management. She has been recognized as one of Fortune’s 34 Leaders Who Are Changing Health Care, one of the 100 Most Influential Women in Silicon Valley, and one of Fierce Biotech’s Top 10 Women in Medical Devices. She was awarded the Lifetime Achievement Award by Global Corporate Venture in 2020 and was selected as an Aspen Institute Henry Crown Fellow. She is a featured “multiplier” in the bestselling book Multipliers: How the Best Leaders Make Everyone Smarter.